Vice President Biologics Discovery @ Ridgeline Discovery (August 2020 - August 2022)
Vice President Antibody Development @ (October 2016 - July 2020)
Senior Director R and D @ MorphoSys AG (November 2004 - September 2016)
Project Leader @ (August 2003 - August 2004)
Team Leader @ MorphoSys AG (November 1999 - July 2003)
Stefanie Urlinger Education
University Erlangen-Nuernberg
Postdoc
1997-1999
Max-Planck-Institute for Biochemistry, Martinsried
Doktor (Ph.D.) (Molecular Biology)
1994-1997
University of Vienna
Visiting researcher (Molecular Biology)
1994-1994
University Regensburg
Dipl. Biol. (Biology)
1989-1994
Stefanie Urlinger Skills
Antibody discovery & development
Antibody engineering
Forschung und Entwicklung
GPCR targeting
Monoklonale Antikörper
Teamführung
Sales
Management
Change Management
Training
Marketing
Strategic Planning
Antibody Discovery and Development
Stefanie Urlinger Summary
Stefanie Urlinger, based in Munich, BY, DE, is currently a Chief Scientific Officer at Cimeio Therapeutics. Stefanie Urlinger brings experience from previous roles at Ridgeline Discovery, iOmx Therapeutics AG, MorphoSys AG and OncoMab GmbH. Stefanie Urlinger holds a 1997 - 1999 Postdoc @ University Erlangen-Nuernberg. With a robust skill set that includes Antibody discovery & development, Antibody engineering, Forschung und Entwicklung, GPCR targeting, Monoklonale Antikörper and more. Stefanie Urlinger has 1 emails and 1 mobile phone numbers on RocketReach.
Looking for a different Stefanie Urlinger?
Find contact details for 700 million professionals.